Enhancing cancer vaccine efficacy via modulation of the tumor microenvironment.
The development of therapeutic cancer vaccines is impacted by immunosuppressive elements in the tumor microenvironment. Most immunogenic cancer proteins are "self," therefore, peripheral tolerance contributes substantially to tumor immune escape. Transforming growth factor beta (TGFbeta) actively modulates both inflammation and tolerance induction. Combining vaccination with agents that disarm TGFbeta will enhance vaccine efficacy.
Tumor Vaccine Group, Center for Translational Medicine in Women's Health, University of Washington, Seattle, Washington 98195-8050, USA. ndisis@u.washington.edu
Mary L
ML
Disis
D000818:Animals; D001324:Autoantigens / Q000276:immunology; D019496:Cancer Vaccines / Q000627:therapeutic use; D005260:Female; D007108:Immune Tolerance; D056747:Immunomodulation; D008297:Male; D051379:Mice; D018448:Models, Immunological; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D016212:Transforming Growth Factor beta / Q000502:physiology*; D019139:Tumor Escape
D001324:Autoantigens; D019496:Cancer Vaccines; D016212:Transforming Growth Factor beta